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Status epilepticus in childhood is a common medical
emergency requiring swift and effective termination in order to
limit subsequent adverse complications. Parenteral pheno-
barbitone is the main agent used in most centres to attain this.
The production of parenteral phenobarbitone in South Africa
stopped in December 2004; this was a worldwide policy by the
suppliers. 
Phenobarbitone is recommended in the most recent
Advanced Paediatric Life Support (APLS) guidelines (Fig. 1).
1
Its withdrawal has even more serious repercussions for the
management of status epilepticus in resource-poor countries
(RPCs). 
Phenobarbitone can be administered by slow intravenous
push or intramuscularly, a route that is often used in RPCs.
2,3
It
is an effective agent for the control of status epilepticus.
4,5
Side-
effects are respiratory depression and lowering of blood
pressure, the underlying disease being the main related factor
and the rate of rise of serum levels.
6
Accordingly it can be and
is used at all levels of hospital care. The authors concur with
the APLS guidelines and have recommended the use of
phenobarbitone for the third line of treatment for the
management of status epilepticus in RPCs (Fig. 2).
7,8
If the supply of parenteral phenobarbitone terminates, the
alternatives for our setting are limited. Lorazepam or other
benzodiazepines are associated with increased risk of
respiratory depression
9
and the risk will increase where
benzodiazepines are already used as first-line treatment. 
Phenytoin is the alternative agent to phenobarbitone in the
APLS algorithm.  Intravenous phenytoin is associated with
fatal haemodynamic complications, serious skin reactions at
the injection site and cardiac arrhythmias.
10
The agent should
be administered into a large vein (but ideally not central), via a
slow infusion over 30 minutes through a syringe driver. The
child should have cardiac monitoring. These facilities for safe
administration are often not available in hospitals in RPCs.
Following the guidelines, the administration of phenytoin takes
three times as long as the slow push of phenobarbitone. The
delayed time to administer therapy may increase the risk of
refractory status epilepticus, which is associated with
subsequent brain damage.
11
Furthermore, the APLS guidelines
recommend measuring levels 60 - 90 minutes after completion
of the infusion, but this is only available in a few tertiary or
research centres in RPCs. Although more economical than the
newer anticonvulsants, parenteral phenytoin is still four times
the cost of phenobarbitone. In addition, it is not as fast or
effective at controlling status epilepticus as phenobarbi-
tone.
4,5,12,13
In conclusion, although pharmaceutical companies may not
make substantial profits from the manufacture of
phenobarbitone, withdrawal of this drug is likely to have a
devastating effect on the outcome of status epilepticus in RPCs.
Currently various bodies are attempting to ensure that this
agent remains available in South Africa. This crisis should be
viewed as an example of the potential dependency of the
medical profession on drug company policy, and the latter’s
potentially catastrophic effects on the care of our patients.
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Parenteral phenobarbitone is an integral part of the
management of status epilepticus, especially in the context of
resource-poor countries. It is highly effective at controlling
seizures. It is safe, cheap, can be given by rapid intravenous
push or intramuscular route, boluses can be repeated, and it is
recommended as part of the Advanced Paediatric Life Support
guidelines. The proposed alternatives lack efficacy, practicality
and/or place the child in status epilepticus at risk of
respiratory compromise. The impact of the loss of parenteral
phenobarbitone would be increased cardiac complications, lack
of early seizure control, prolonged seizures resulting in brain
damage and systemic complications. Increased numbers of
patients will require artificial ventilation in centres without
facilities, and centres with facilities will be unable to cope with
the load of ventilated patients because of lack of safe transport
systems and bed space.
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Airway
High-flow oxygen
Don't ever forget glucose
Vascular access ?
Yes No
Lorazepam Diazepam (rectal)
0.1 mg/kg IV/IO 0.5 mg/kg OR
Midazolam (buccal)
0.5 mg/kg
Lorazepam YES Vascular access? 
0.1 mg/kg IV/IO                                                                
NO
Paraldehyde 0.4 ml/kg PR
i.e. 0.8 ml/kg of prepared solution 
Phenytoin 18 mg/kg IV/IO over 30 minutes      
Or if already on phenytoin give phenobarbitone 
20 mg/kg IV/IO over 10 minutes
Rapid sequence induction with thiopental sodium (thiopentone) 4
mg/kg IV/IO
Fig. 1. APLS status epilepticus algorithm (2005)1 (IV = intravenous; IO
= intra-osseous; PR = per rectum).
PR diazepam (0.5 mg/kg)
IV access IV diazepam  (0.3 mg/kg)
(take bloods for glucose, gas, electrolytes, 
full blood count and culture)
Access failure/delay – gain IO access or 
intranasal midazolam 200 µg/kg
IV phenobarbitone (20 mg/kg)
Repeat phenobarbitone (10 mg/kg)
Repeat phenobarbitone (10 mg/kg)
Refer to PICU for intubation and sodium pentothal
infusion 
Alternatives: (i) lorazepam (0.1 mg/kg), a faster-acting alternative to
diazepam for bolus IV intervention; (ii) midazolam intranasally (200
µg/kg) or sublingually (500 µg/kg) if there is no venous access; (iii)
midazolam infusion  loading at 200 µg/kg by slow IV injection, then
titrating an infusion between 30 µg/kg/h and 300 µg/kg/h –
alternatively, clonazepam (Rivotril) infusion if seizure control is not
gained after the first phenobarbitone infusion; (iv) phenytoin (20
mg/kg over 20 minutes) if there is known adverse reaction to
phenobarbitone (monitor for cardiac arrhythmias); (v) watch carefully
for drug-related respiratory depression; and (vi) intubation, ventilation
and administration of sodium pentothal infusion should only be
performed in a centre with trained anaesthetic and paediatric intensive
care.
PR = per rectum; IV access = if IV access available; IO = intra-osseous;
PICU = paediatric intensive care unit; ABCD = airway, breathing,
circulation, drugs.
Fig. 2. Management of status epilepticus in South Africa8 –
ABCD (oxygen, monitor saturation, pulse and blood pressure,
glucose).
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